Table 1

Asthma control end points, baseline and during SMART therapy

	Rabe et al10	Scicchitano et al11	O'Byrne et al 12	Rabe et al14	Vogelmeier et al15	Kuna et al21	Bousquet et al19	Weighted averages
N (SMART arm)	354	947	925	1107	1067	1052	1151
Study duration	6 months	12 months	12 months	12 months	12 months	6 months	6 months	N/A
Symptom-free days (%)	B: 29.6	B: 9.8	B: 23.1	B: 9.2^*	NA	B: 9.3	B: 10.7	B: 13.2
Symptom-free days (%)	T: 55.1	T: 41.7	T: 54	T: 40.3^*	NA	T: 44.2	T: 47.2	T: 46.0
As-needed reliever use inhalations/day)	B: 1.64	B: 1.9	B: 2.46	B: 1.8	B: 2.6	B: 2.29	B: 2.23	B: 2.18
As-needed reliever use inhalations/day)	T: 1.04	T: 0.90	T: 1.01	T: 1.02	T: 0.59^†	T: 1.02	T: 0.95	T: 0.92
Reliever-free days (%)	B: 24.3	B: 29.3	B: 8.2	B: N/A	NA	B: 8.9	B: 10.3	B: 14.7
Reliever-free days (%)	T: 55.3	T: 59.8	T: 55	T: 52	NA	T: 56	T: 58.2	T: 56.1
Nights with awakenings (%)	B: 13.3	B: 22.6	B: 21.8	B: 31.1	NA	B: 33.7	B: 32.1	B: 27.7
Nights with awakenings (%)	T: 6.5	T: 9.4	T: 9.0	T: 14.1	NA	T: 14.1	T: 12.0	T: 11.5
Severe exacerbations (events/patient/year)	0.08	0.23	0.19	0.19	0.24	0.24	0.25	0.22

↵* 24-hour period.
↵† For weeks 0–4 (during which morning and evening budesonide/formoterol doses were unchanged at two inhalations of 200/6).
B, baseline; T, treatment; NA, not available; N/A, not applicable; SMART, single maintenance and reliever therapy.